礼来公司宣布,其药物Foundayo在Achieve-4临床试验中展现出的总体安全性与耐受性特征,与先前进行的多项试验结果以及胰高血糖素样肽-1(GLP-1)类药物类别的已知特征基本保持一致。
礼来公司宣布,其药物Foundayo在Achieve-4临床试验中展现出的总体安全性与耐受性特征,与先前进行的多项试验结果以及胰高血糖素样肽-1(GLP-1)类药物类别的已知特征基本保持一致。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.